ArticleCancer2026
The landscape of chemotherapy modifications among women treated for stage I-IIIA breast cancer.
Article in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
backgroundIn the delivery of cancer care, patients may experience modifications to their intended chemotherapy regimen for reasons such as toxicity, tolerability, and scheduling challenges. Understanding modifications from the intended chemotherapy in the real-world setting of cancer care may affect treatment planning and inferences of real-world treatment effectiveness.
methodsBy leveraging data from the Optimal Breast Cancer Chemotherapy Dosing Study, this research studied 12,558 women receiving chemotherapy for primary stage I-IIIA breast cancer at Kaiser Permanente Northern California (2006-2019) and Kaiser Permanente Washington (2004-2015). Modifications in chemotherapy administered from intended, both overall and by regimen, are described. Prevalence ratios (PRs) were calculated for associations between regimen attributes and treatment modifications via generalized linear models of the Poisson family with a log-link function and robust standard errors.
resultsIntent to receive a guideline-concordant regimen was associated with a lower likelihood of modifications from the intended chemotherapy (vs. non-guideline concordant) (PR, 0.74; 95% CI, 0.69-0.79), as was receiving a dose-dense regimen (vs. non-dose dense) (PR, 0.84; 95% CI, 0.78-0.91). Those receiving any neoadjuvant chemotherapy (vs. adjuvant only) were more likely to have modifications from the intended chemotherapy (PR, 1.29; 95% CI, 1.19-1.41). Increasing numbers of cycles and drugs administered were associated with a higher likelihood of modifications (p
conclusionsBreast cancer chemotherapy regimens used in the real-world setting were examined. Chemotherapy modifications varied markedly by regimen and by characteristics of the regimen administered. Given that more than one in three women in this cohort did not receive chemotherapy as intended, these novel findings may be informative in treatment planning and for future research assessing real-world treatment effectiveness.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.